Hemispherx hopes new 'PDUFA V' measure will save Ampligen
04:20 EDT 2 Aug 2012 | SCRIP
With the fate of Hemispherx Biopharma's chronic fatigue syndrome (CFS) therapy Ampligen once again in the hands of the US FDA, the Philadelphia biotech made no bones about warning investors on 1 August that there were no assurances the data in the....
Original Article: Hemispherx hopes new 'PDUFA V' measure will save Ampligen
More From BioPortfolio on "Hemispherx hopes new 'PDUFA V' measure will save Ampligen"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
